Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes - Wikidata - awgldk - TriplyDB

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes

http://www.wikidata.org/entity/Q35179964

about

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass Treatment of prediabetes Assessment of pancreatic β-cell function: review of methods and clinical applications Interventions to preserve beta-cell function in the management and prevention of type 2 diabetes Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes Effects of GLP-1 on appetite and weight β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment.Postprandial serum C-peptide value is the optimal index to identify patients with non-obese type 2 diabetes who require multiple daily insulin injection: Analysis of C-peptide values before and after short-term intensive insulin therapy.GLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activation Bariatric surgery and obesity: influence on the incretins Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.Profound defects in β-cell function in screen-detected type 2 diabetes are not improved with glucose-lowering treatment in the Early Diabetes Intervention Program (EDIP).Incretin-based therapies in prediabetes: Current evidence and future perspectives Exenatide's effect in reducing weight and glycosylated hemoglobin level in an Arab population with type 2 diabetes Importance of Beta Cell Function for the Treatment of Type 2 Diabetes Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study Potential use of exenatide for the treatment of obesity.Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature.Evolution of exenatide as a diabetes therapeutic.Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatment Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings.Obesity and appetite control Coming full circle in diabetes mellitus: from complications to initiation.Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes.The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy.What are the pharmacotherapy options for treating prediabetes?Implications of incretin-based therapies on cardiovascular disease.Combination immunotherapies for type 1 diabetes mellitus.

P2860

Q24598747-C5CBA530-E4CA-4F3A-9E0C-53B6DB4ABD05 Q26749089-9B227766-F5AF-4CDA-8847-2B27FAAA1D0E Q26783350-9AD4ED47-D111-4A3D-B45E-E704886A0D45 Q26829445-A55BC58B-DA35-454A-A5A1-123F9087B936 Q26830871-ACBBD5ED-9C8B-406A-A2DD-90B6A57A6EE0 Q26861768-3A858A19-43FF-4457-BB00-3ED996CD5EB8 Q27011627-CF664012-5E68-4C3D-B569-87DAA2932403 Q27692665-704CC0DC-054B-4916-991C-CD583D96766D Q28088578-EA00E823-51BC-42EB-8298-74D17595E7B3 Q30572405-D7E2AA9B-4EBF-447C-80F4-E5667DB93DA9 Q30597265-F9BCF2D4-94D6-403F-9701-602D2F360508 Q33570085-339CEAD2-113A-4B24-809F-1BCB53FF2533 Q33607770-1711E43B-6151-4DC1-9AF7-AD338D64F7C9 Q33753096-94826FA3-F2B8-461D-B9D3-96905C4FBB42 Q33838154-10DDA715-FB1C-40D1-8A5F-57D1A53AB132 Q34073469-0965F4E0-81B3-4DEB-855C-DE04FBF14D45 Q34498840-5762C2B4-54F3-434A-8A00-3E320ADC07BA Q34699191-B10ABB19-5AF8-42D7-B6AD-6E04D1501633 Q35183579-65A3DEDA-5ED0-4661-A8EE-059F7BEC224C Q35667116-AAB6F0BA-D8CC-49A1-980D-6FB914719AEC Q35688369-30B3DC4A-0D62-4A03-875E-57266CA4C9C4 Q36391466-EA5FC7E0-1A1B-4517-894B-39CFA0E444C2 Q36584204-F317D673-E035-495E-B6D8-8A5B0515B013 Q36592820-3E220BE1-BF63-43DE-98E9-5F0BC3E02AC7 Q36872178-5DA0C155-E124-4511-945D-9240EA215409 Q36877205-5CD56EAD-483B-4452-AEF6-ADB29B628C4D Q37193295-2B1C1A3A-1215-4BCB-A908-5C4A302D574B Q37577129-1EB6C4DC-134E-496F-844A-2D6CCB8A171D Q37577162-CAA2B9F1-5A90-4442-9359-8F88D5CEA984 Q37992259-0D849F02-0051-4625-8F8E-D5A58EFD654F Q38005223-C3AA2EA3-FA74-4001-8C13-8A7230B444F4 Q38014516-A81346A7-44EE-4F8A-8AC8-9A2C3D55CFBF Q38035293-27BFC047-5595-40E6-8696-5542441D2459 Q38072272-E0824E6A-06AB-4212-BF34-5359A5BC8F1E Q38129446-E5CF6ACB-8B56-47C3-B645-E51C9903FF4B Q38174279-D1DF0E3C-7CEE-4F36-AD30-1D0A0FA53B48 Q38202156-893D1BE6-A4BC-4AB0-8B64-C6AD220D8424 Q38241464-B03893F1-6E7F-49E0-803F-B035A082DA29 Q38264374-C14019CA-A7B9-4447-886B-EA13323C2EE6 Q38358009-845A4B20-F5D2-4E0B-AB64-1586FD025274

P2860

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes

http://www.wikidata.org/entity/Q35179964

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Effects of exenatide on measur ...... patients with type 2 diabetes

@ast

Effects of exenatide on measur ...... patients with type 2 diabetes

@en

type

label

Effects of exenatide on measur ...... patients with type 2 diabetes

@ast

Effects of exenatide on measur ...... patients with type 2 diabetes

@en

prefLabel

Effects of exenatide on measur ...... patients with type 2 diabetes

@ast

Effects of exenatide on measur ...... patients with type 2 diabetes

@en

P1433

Q35179964-7DAA9C9D-E97C-42C9-A383-89AE8BBE94A8

P1476

Q35179964-F1377809-35AF-4AF0-A0D5-82E07C156D17

P2093

Q35179964-0B739976-483F-4DF2-84EE-63E2399651FA

Q35179964-46016A85-341F-49F3-9E55-87822A55E04B

Q35179964-5E85FB40-7217-47E3-A2A3-8678EA317565

Q35179964-5FE01B62-4F7A-43EF-A4B2-A2FCD0E83C6B

Q35179964-66943A4F-C3AA-410F-AF29-3669CA540E9A

Q35179964-6A25EA2F-00CA-4550-AAD6-1697A323942F

Q35179964-B32BFBF6-671F-4B6F-AB6D-ACD8DA71B291

P2860

Q35179964-02D1EAAC-D25C-4665-BD29-C2A468E27592

Q35179964-04B5F79B-6325-4FAE-BD55-4FDC26A68149

Q35179964-0BAB427A-8A37-4BF9-9E78-172D074AFD29

Q35179964-13CE703B-9B69-4279-9CA6-BD7B2E21488F

Q35179964-27B73EF1-3A00-43DD-9970-947F62532F3C

Q35179964-2D080E61-FC98-4198-BDFF-559064C04714

Q35179964-31DF14DF-FA31-4DFA-8F52-6F6A81B0BADD

Q35179964-469A2F6E-1731-45E8-AC6C-1B09ED712542

Q35179964-5D005921-8BD4-4149-B7D9-22D3FFDCDF2A

Q35179964-6505927E-6B29-4FFE-B31B-163C73DD25DE

P304

Q35179964-D25ADE52-D697-42BD-AB43-6E0C5A83856A

P31

Q35179964-4621B57A-D6D3-435F-BC36-E236E6314B08

P356

Q35179964-478A284E-7C55-4956-9611-92D3F76D09CD

P407

Q35179964-E044946F-F111-4B80-BD4E-82BE593EDE36

P433

Q35179964-50AEBC37-DB10-404B-95B3-17191CB46B18

P478

Q35179964-1E159151-7173-40FC-9DCF-DEF45E05AB5F

P50

Q35179964-396BD37D-9687-4C3A-905D-9B9233F636E7

Q35179964-ADA48ABD-1959-439E-A5CD-D2DC574DC370

P577

Q35179964-DDED6510-7439-411A-99F1-116A3A2E69BE

P5875

Q35179964-C425D63D-6094-492F-956E-693D0CFAC56A

P698

Q35179964-16FA24BC-B2CF-4EA9-B8EC-DFC458D0E9C5

P921

Q35179964-566693D5-2461-4D8C-85A4-AD47C9410497

Q35179964-6393D258-156E-4893-8FA4-BC64A9545018

P932

Q35179964-F7C8A684-A77E-402D-ABB1-D6E8F5B6151B

P356

P1433

P1476

Effects of exenatide on measur ...... patients with type 2 diabetes

@en

P2093

Anja Cornér

http://www.w3.org/2001/XMLSchema#string

Bjorn Eliasson

http://www.w3.org/2001/XMLSchema#string

Marja-Riitta Taskinen

http://www.w3.org/2001/XMLSchema#string

Mathijs C Bunck

http://www.w3.org/2001/XMLSchema#string

Michaela Diamant

http://www.w3.org/2001/XMLSchema#string

Rimma M Shaginian

http://www.w3.org/2001/XMLSchema#string

Ulf Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Biology of incretins: GLP-1 and GIP

Weight loss therapy improves pancreatic endocrine function in obese older adults

Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009

Effect of ramipril on the incidence of diabetes.

Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition

Glucose clamp technique: a method for quantifying insulin secretion and resistance.

P304

2041-2047

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC11-0291

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

Hannele Yki-Järvinen

Robert J. Heine

P577

2011-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51596993

http://www.w3.org/2001/XMLSchema#string

P698

21868779

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3161303

http://www.w3.org/2001/XMLSchema#string